Skip to main content

Table 2 Constitutive expression and increase of CD26 at the surface of human colorectal carcinoma cells by anticancer drugs

From: Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26

Cell line Basal CD26 expression (cpm/105 cells) Drug treatment
   5-FU Cis Vin MTX
   Maximal increase (% over control)
HT-29 1,300 ± 140 30 ± 5.8** 72 ± 26*** 41 ± 10** 26 ± 6.4**
T84 780 ± 69 84 ± 14* 61 ± 42 78 ± 6.6 73 ± 42
HRT-18 370 ± 64 17 ± 9.1* 19 ± 9.1 23 ± 12 18 ± 9.4**
SW480 55 ± 15 96 ± 58* 90 ± 66 100 ± 59** 170 ± 150
SW620 26 ± 12 36 ± 31 28 ± 30 45 ± 43 53 ± 49
  1. The relative basal cell-surface protein expression for each cell line was summarized from 12–5 independent experiments. Cells were treated with drugs (5-FU, 5-fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell surface expression of CD26 was determined by radioimmunobinding assay 48 h later. Maximal up-regulation of CD26 was recorded from 3–7 independent dose–response experiments for each drug and cell line. Data are shown as mean % increases ± SE for the moderate/high CD26-expressing cell lines, and mean numerical increases (cpm/105 cells) ± SE for the low expressers. *, significant increase due to drug, P < 0.05; **, P < 0.01; ***, P < 0.001, using paired t-test